BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Haque S, Cook K, Sahay G, Sun C. RNA-Based Therapeutics: Current Developments in Targeted Molecular Therapy of Triple-Negative Breast Cancer. Pharmaceutics 2021;13:1694. [PMID: 34683988 DOI: 10.3390/pharmaceutics13101694] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Li H, Zha S, Li H, Liu H, Wong KL, All AH. Polymeric Dendrimers as Nanocarrier Vectors for Neurotheranostics. Small 2022;18:e2203629. [PMID: 36084240 DOI: 10.1002/smll.202203629] [Reference Citation Analysis]
2 Katopodi T, Petanidis S, Tsavlis D, Anestakis D, Charalampidis C, Chatziprodromidou I, Eskitzis P, Zarogoulidis P, Kosmidis C, Matthaios D, Porpodis K. Engineered multifunctional nanocarriers for controlled drug delivery in tumor immunotherapy. Front Oncol 2022;12:1042125. [DOI: 10.3389/fonc.2022.1042125] [Reference Citation Analysis]
3 Wang X, Chen T, Li C, Li W, Zhou X, Li Y, Luo D, Zhang N, Chen B, Wang L, Zhao W, Fu S, Yang Q. CircRNA-CREIT inhibits stress granule assembly and overcomes doxorubicin resistance in TNBC by destabilizing PKR. J Hematol Oncol 2022;15:122. [PMID: 36038948 DOI: 10.1186/s13045-022-01345-w] [Reference Citation Analysis]
4 Lu Y, Xiao Y, Yang J, Su H, Zhang X, Su F, Tian B, Zhao D, Ling X, Zhang T, Roy S. TRIM65 Promotes Malignant Cell Behaviors in Triple-Negative Breast Cancer by Impairing the Stability of LATS1 Protein. Oxidative Medicine and Cellular Longevity 2022;2022:1-16. [DOI: 10.1155/2022/4374978] [Reference Citation Analysis]
5 Lu X, Zhong J, Liu L, Zhang W, Zhao S, Chen L, Wei Y, Zhang H, Wu J, Chen W, Ge F. The function and regulatory mechanism of RNA-binding proteins in breast cancer and their future clinical treatment prospects. Front Oncol 2022;12:929037. [DOI: 10.3389/fonc.2022.929037] [Reference Citation Analysis]
6 Davodabadi F, Sarhadi M, Arabpour J, Sargazi S, Rahdar A, Díez-Pascual AM. Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches. J Control Release 2022;349:844-75. [PMID: 35908621 DOI: 10.1016/j.jconrel.2022.07.036] [Reference Citation Analysis]
7 Nahvi I, Belkahla S, Biswas S, Chakraborty S. A Review on Nanocarrier Mediated Treatment and Management of Triple Negative Breast Cancer: A Saudi Arabian Scenario. Front Oncol 2022;12:953865. [DOI: 10.3389/fonc.2022.953865] [Reference Citation Analysis]
8 Landry I, Sumbly V, Vest M. Advancements in the Treatment of Triple-Negative Breast Cancer: A Narrative Review of the Literature. Cureus. [DOI: 10.7759/cureus.21970] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]